An “inflammatory” subtype of human SCLC has recently been identified, which has increased immunogenicity, is more responsive to immune checkpoint blockade (ICB), and can emerge in subpopulations of tumors cells that lose ASCL1 after recurrence from chemotherapy36–38. The gene discussed is ASCL1; the disease is small cell lung carcinoma.